0001209191-24-003269.txt : 20240213 0001209191-24-003269.hdr.sgml : 20240213 20240213201730 ACCESSION NUMBER: 0001209191-24-003269 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240209 FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Seely Lynn CENTRAL INDEX KEY: 0001327111 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40502 FILM NUMBER: 24631359 MAIL ADDRESS: STREET 1: 501 2ND STREET STREET 2: SUITE 211 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lyell Immunopharma, Inc. CENTRAL INDEX KEY: 0001806952 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 833006753 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650 695-0677 MAIL ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-02-09 0 0001806952 Lyell Immunopharma, Inc. LYEL 0001327111 Seely Lynn C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO 0 Common Stock 2024-02-09 4 A 0 200000 0.00 A 200000 D The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. /s/ Charles Newton, as Attorney-in-Fact 2024-02-13